Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2006

View Archived Issues

Heidelberg Pharma report on improved efficacy of novel alovudine prodrug

Targeting PKC beta for the treatment of diabetic cardiomyopathy

Emerging targets and molecular markers in head and neck cancer

Phase I findings for RP-101 with gemcitabine in advanced pancreatic cancer

Expiration dates confirmed and new agreement for golimumab

Vicriviroc demonstrates potent and sustained viral suppression in HIV

Milestone in collaboration between Ortec and ES Cell International

TAFA-93 shows promise in phase I studies

Japanese marketing alliance discontinued for Ketek

QD-3: a novel peptidic HIV-1 fusion inhibitor for drug-resistant viruses

Preclinical studies confirm that bevirimat is non-teratogenic

Aptivus/ritonavir efficacious and safe in PI-resistant pediatric patients

Recent Dainippon patent describes new treatment option for cardiovascular disorders

Recent patents disclose new therapeutic agents for anxiety, depression, etc.

Novel antidiabetic compounds disclosed by Sirtris in recent patent

New Schering patent describes therapeutic agents for allergic and respiratory disorders

Glypromate shows good pharmacokinetic profile

CoGenesys and Vegenics sign VEGF licensing agreement

Stromectol approved in Japan for treatment of scabies

Alnylam grants Calando license under InterfeRx program

Canadian approval for Azilect in Parkinson's disease

ATG-003 begins phase I testing for AMD

Dynavax's ISS vaccine shows potential as universal flu vaccine

ASF-1075 studied for psoriasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...